Ratings by Raymond James (Ryan Deschner)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/12/2026 | Dianthus Therapeutics | DNTH | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/10/2026 | Dianthus Therapeutics | DNTH | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/10/2026 | ADMA Biologics | ADMA | New Coverage | Outperform (N/A) |
8.12 (8.31) |
2.34% | Details | |
| 6/4/2026 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/2/2026 | Vera Therapeutics | VERA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/13/2026 | Inflarx NV | IFRX | Upgrade | Strong Buy (Outperform) |
2.43 (1.81) |
-25.51% | Details | |
| 5/12/2026 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/24/2026 | Viking Therapeutic | VKTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/20/2026 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/13/2026 | Korro Bio Inc. | KRRO | Upgrade | Outperform (Market Perform) |
11.76 (12.99) |
10.46% | Details | |
| 3/5/2026 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/2/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/23/2026 | Palvella Therapeutics | PVLA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/31/2025 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2025 | Palvella Therapeutics | PVLA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/2/2025 | Vera Therapeutics | VERA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/19/2025 | Palvella Therapeutics | PVLA | Upgrade | Strong Buy (Outperform) |
82.94 (113.10) |
36.36% | Details | |
| 11/11/2025 | Inflarx NV | IFRX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/4/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/14/2025 | Tvardi Therapeutics Inc | TVRD | Downgrade | Market Perform (Outperform) |
6.69 (2.63) |
-60.69% | Details | |
| 9/26/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/14/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/13/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/6/2025 | Palvella Therapeutics | PVLA | New Coverage | Outperform (N/A) |
37.20 (82.94) |
122.96% | Details | |
| 8/5/2025 | Ardelyx, Inc | ARDX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/14/2025 | Tvardi Therapeutics Inc | TVRD | New Coverage | Outperform (N/A) |
27.35 (6.69) |
-75.54% | Details | |
| 6/30/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/11/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/6/2025 | Vera Therapeutics | VERA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/2/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 6/2/2025 | Trevi Therapeutics | TRVI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/29/2025 | Inflarx NV | IFRX | Downgrade | Outperform (Strong Buy) |
1.82 (2.43) |
33.52% | Details | |
| 5/28/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/27/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/21/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/20/2025 | Trevi Therapeutics | TRVI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/16/2025 | Inozyme Pharma Inc. | INZY | Downgrade | Market Perform (Outperform) |
1.42 (4.00) |
181.69% | Details | |
| 5/12/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/2/2025 | Ardelyx, Inc | ARDX | Downgrade | Outperform (Strong Buy) |
5.47 (6.05) |
10.6% | Details | |
| 3/31/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/24/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/20/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/20/2025 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/19/2025 | Trevi Therapeutics | TRVI | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/10/2025 | Trevi Therapeutics | TRVI | Upgrade | Strong Buy (Outperform) |
4.30 (17.21) |
300.23% | Details | |
| 1/13/2025 | Inozyme Pharma Inc. | INZY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2024 | Inozyme Pharma Inc. | INZY | New Coverage | Outperform (N/A) |
2.96 (4.00) |
35.14% | Details | |
| 11/15/2024 | Omega Therapeutics | OMGA | Downgrade | Market Perform (Outperform) |
1.01 (0.14) |
-86.14% | Details | |
| 10/8/2024 | Liquidia Technologies | LQDA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/30/2024 | Trevi Therapeutics | TRVI | New Coverage | Outperform (N/A) |
2.91 (4.30) |
47.77% | Details | |
| 8/19/2024 | Liquidia Technologies | LQDA | Upgrade | Strong Buy (Outperform) |
14.11 (71.07) |
403.69% | Details | |
| 8/16/2024 | Liquidia Technologies | LQDA | New Coverage | Outperform (N/A) |
13.83 (71.07) |
413.88% | Details | |
| 8/13/2024 | ARS Pharmaceuticals Inc | SPRY | Upgrade | Strong Buy (Outperform) |
10.88 (9.65) |
-11.31% | Details | |
| 7/25/2024 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Outperform (N/A) |
10.40 (9.65) |
-7.21% | Details | |
| 6/18/2024 | Omega Therapeutics | OMGA | New Coverage | Outperform (N/A) |
1.86 (0.14) |
-92.47% | Details | |
| 1/26/2024 | Vera Therapeutics | VERA | Upgrade | Strong Buy (Outperform) |
25.31 (35.09) |
38.64% | Details | |
| 12/18/2023 | Ardelyx, Inc | ARDX | New Coverage | Strong Buy (N/A) |
5.91 (5.47) |
-7.45% | Details |
